Genomic Landscape of Intramedullary Spinal Cord Gliomas

Ming Zhang, Rajiv R. Iyer, Tej D. Azad, Qing Wang, Tomas Garzon-Muvdi, Joanna Wang, Ann Liu, Peter Burger, Charles Eberhart, Fausto J. Rodriguez, Daniel M. Sciubba, Jean Paul Wolinsky, Ziya Gokaslan, Mari L. Groves, George I. Jallo, Chetan Bettegowda

Research output: Contribution to journalArticle

Abstract

Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms that have limited treatment options and are associated with high rates of morbidity and mortality. To better understand the genetic basis of these tumors we performed whole exome sequencing on 45 tumors and matched germline DNA, including twenty-nine spinal cord ependymomas and sixteen astrocytomas. Though recurrent somatic mutations in IMSCTs were rare, we identified NF2 mutations in 15.7% of tumors (ependymoma, N = 7; astrocytoma, N = 1), RP1 mutations in 5.9% of tumors (ependymoma, N = 3), and ESX1 mutations in 5.9% of tumors (ependymoma, N = 3). We further identified copy number amplifications in CTU1 in 25% of myxopapillary ependymomas. Given the paucity of somatic driver mutations, we further performed whole-genome sequencing of 12 tumors (ependymoma, N = 9; astrocytoma, N = 3). Overall, we observed that IMSCTs with intracranial histologic counterparts (e.g. glioblastoma) did not harbor the canonical mutations associated with their intracranial counterparts. Our findings suggest that the origin of IMSCTs may be distinct from tumors arising within other compartments of the central nervous system and provides the framework to begin more biologically based therapeutic strategies.

Original languageEnglish (US)
Article number18722
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Glioma
Ependymoma
Spinal Cord
Spinal Cord Neoplasms
Mutation
Neoplasms
Astrocytoma
Exome
Glioblastoma
Central Nervous System
Genome
Morbidity
Mortality
DNA

ASJC Scopus subject areas

  • General

Cite this

Zhang, M., Iyer, R. R., Azad, T. D., Wang, Q., Garzon-Muvdi, T., Wang, J., ... Bettegowda, C. (2019). Genomic Landscape of Intramedullary Spinal Cord Gliomas. Scientific reports, 9(1), [18722]. https://doi.org/10.1038/s41598-019-54286-9

Genomic Landscape of Intramedullary Spinal Cord Gliomas. / Zhang, Ming; Iyer, Rajiv R.; Azad, Tej D.; Wang, Qing; Garzon-Muvdi, Tomas; Wang, Joanna; Liu, Ann; Burger, Peter; Eberhart, Charles; Rodriguez, Fausto J.; Sciubba, Daniel M.; Wolinsky, Jean Paul; Gokaslan, Ziya; Groves, Mari L.; Jallo, George I.; Bettegowda, Chetan.

In: Scientific reports, Vol. 9, No. 1, 18722, 01.12.2019.

Research output: Contribution to journalArticle

Zhang, M, Iyer, RR, Azad, TD, Wang, Q, Garzon-Muvdi, T, Wang, J, Liu, A, Burger, P, Eberhart, C, Rodriguez, FJ, Sciubba, DM, Wolinsky, JP, Gokaslan, Z, Groves, ML, Jallo, GI & Bettegowda, C 2019, 'Genomic Landscape of Intramedullary Spinal Cord Gliomas', Scientific reports, vol. 9, no. 1, 18722. https://doi.org/10.1038/s41598-019-54286-9
Zhang M, Iyer RR, Azad TD, Wang Q, Garzon-Muvdi T, Wang J et al. Genomic Landscape of Intramedullary Spinal Cord Gliomas. Scientific reports. 2019 Dec 1;9(1). 18722. https://doi.org/10.1038/s41598-019-54286-9
Zhang, Ming ; Iyer, Rajiv R. ; Azad, Tej D. ; Wang, Qing ; Garzon-Muvdi, Tomas ; Wang, Joanna ; Liu, Ann ; Burger, Peter ; Eberhart, Charles ; Rodriguez, Fausto J. ; Sciubba, Daniel M. ; Wolinsky, Jean Paul ; Gokaslan, Ziya ; Groves, Mari L. ; Jallo, George I. ; Bettegowda, Chetan. / Genomic Landscape of Intramedullary Spinal Cord Gliomas. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{d6dfb9791680419eb9bfe0f0e7df96ae,
title = "Genomic Landscape of Intramedullary Spinal Cord Gliomas",
abstract = "Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms that have limited treatment options and are associated with high rates of morbidity and mortality. To better understand the genetic basis of these tumors we performed whole exome sequencing on 45 tumors and matched germline DNA, including twenty-nine spinal cord ependymomas and sixteen astrocytomas. Though recurrent somatic mutations in IMSCTs were rare, we identified NF2 mutations in 15.7{\%} of tumors (ependymoma, N = 7; astrocytoma, N = 1), RP1 mutations in 5.9{\%} of tumors (ependymoma, N = 3), and ESX1 mutations in 5.9{\%} of tumors (ependymoma, N = 3). We further identified copy number amplifications in CTU1 in 25{\%} of myxopapillary ependymomas. Given the paucity of somatic driver mutations, we further performed whole-genome sequencing of 12 tumors (ependymoma, N = 9; astrocytoma, N = 3). Overall, we observed that IMSCTs with intracranial histologic counterparts (e.g. glioblastoma) did not harbor the canonical mutations associated with their intracranial counterparts. Our findings suggest that the origin of IMSCTs may be distinct from tumors arising within other compartments of the central nervous system and provides the framework to begin more biologically based therapeutic strategies.",
author = "Ming Zhang and Iyer, {Rajiv R.} and Azad, {Tej D.} and Qing Wang and Tomas Garzon-Muvdi and Joanna Wang and Ann Liu and Peter Burger and Charles Eberhart and Rodriguez, {Fausto J.} and Sciubba, {Daniel M.} and Wolinsky, {Jean Paul} and Ziya Gokaslan and Groves, {Mari L.} and Jallo, {George I.} and Chetan Bettegowda",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-54286-9",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Genomic Landscape of Intramedullary Spinal Cord Gliomas

AU - Zhang, Ming

AU - Iyer, Rajiv R.

AU - Azad, Tej D.

AU - Wang, Qing

AU - Garzon-Muvdi, Tomas

AU - Wang, Joanna

AU - Liu, Ann

AU - Burger, Peter

AU - Eberhart, Charles

AU - Rodriguez, Fausto J.

AU - Sciubba, Daniel M.

AU - Wolinsky, Jean Paul

AU - Gokaslan, Ziya

AU - Groves, Mari L.

AU - Jallo, George I.

AU - Bettegowda, Chetan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms that have limited treatment options and are associated with high rates of morbidity and mortality. To better understand the genetic basis of these tumors we performed whole exome sequencing on 45 tumors and matched germline DNA, including twenty-nine spinal cord ependymomas and sixteen astrocytomas. Though recurrent somatic mutations in IMSCTs were rare, we identified NF2 mutations in 15.7% of tumors (ependymoma, N = 7; astrocytoma, N = 1), RP1 mutations in 5.9% of tumors (ependymoma, N = 3), and ESX1 mutations in 5.9% of tumors (ependymoma, N = 3). We further identified copy number amplifications in CTU1 in 25% of myxopapillary ependymomas. Given the paucity of somatic driver mutations, we further performed whole-genome sequencing of 12 tumors (ependymoma, N = 9; astrocytoma, N = 3). Overall, we observed that IMSCTs with intracranial histologic counterparts (e.g. glioblastoma) did not harbor the canonical mutations associated with their intracranial counterparts. Our findings suggest that the origin of IMSCTs may be distinct from tumors arising within other compartments of the central nervous system and provides the framework to begin more biologically based therapeutic strategies.

AB - Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms that have limited treatment options and are associated with high rates of morbidity and mortality. To better understand the genetic basis of these tumors we performed whole exome sequencing on 45 tumors and matched germline DNA, including twenty-nine spinal cord ependymomas and sixteen astrocytomas. Though recurrent somatic mutations in IMSCTs were rare, we identified NF2 mutations in 15.7% of tumors (ependymoma, N = 7; astrocytoma, N = 1), RP1 mutations in 5.9% of tumors (ependymoma, N = 3), and ESX1 mutations in 5.9% of tumors (ependymoma, N = 3). We further identified copy number amplifications in CTU1 in 25% of myxopapillary ependymomas. Given the paucity of somatic driver mutations, we further performed whole-genome sequencing of 12 tumors (ependymoma, N = 9; astrocytoma, N = 3). Overall, we observed that IMSCTs with intracranial histologic counterparts (e.g. glioblastoma) did not harbor the canonical mutations associated with their intracranial counterparts. Our findings suggest that the origin of IMSCTs may be distinct from tumors arising within other compartments of the central nervous system and provides the framework to begin more biologically based therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=85076403792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076403792&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-54286-9

DO - 10.1038/s41598-019-54286-9

M3 - Article

C2 - 31822682

AN - SCOPUS:85076403792

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 18722

ER -